Vitamin Shoppe (NYSE: VSI) had its target price trimmed by JPMorgan Chase from $73.00 to $70.00 in a research note issued to investors on Wednesday. The firm currently has an overweight rating on the stock.
“[O]rganic store growth was ratcheted back down to 8.5% from 10% only five months after being ratcheted up, and VSI cited slight slippage in its 2013 private label product acceleration (after speaking quite optimistically just a month ago). Combined with the shift in tone from ICR, we believe investors either felt misled or questioned the degree of items on management’s plate. Indeed, the dramatic sell off in the stock seemed to carry some anger with it today. Realistically, we expected it to be down but not even half the 18% drop experienced following earnings.,” the firm’s analyst commented.
Several other analysts have also recently commented on the stock. Analysts at Barclays Capital cut their price target on shares of Vitamin Shoppe from $61.00 to $58.00 in a research note to investors on Wednesday. They now have an equal weight rating on the stock. Separately, analysts at Credit Suisse cut their EPS estimates on shares of Vitamin Shoppe in a research note on Wednesday. They now have an outperform rating and a $65.00 price target on the stock. They previously had a $75.00 price target on the stock. Finally, analysts at Deutsche Bank cut their price target on shares of Vitamin Shoppe from $56.00 to $55.00 in a research note to investors on Wednesday. They now have a hold rating on the stock.
Six equities research analysts have rated the stock with a buy rating, one has assigned an overweight rating, and eight have assigned a hold rating to the company’s stock. The company currently has a consensus rating of overweight and an average target price of $62.91.
Shares of Vitamin Shoppe traded down 1.18% during mid-day trading on Wednesday, hitting $51.93. Vitamin Shoppe has a one year low of $41.62 and a one year high of $65.93. The stock’s 50-day moving average is currently $60.19. The company has a market cap of $1.567 billion and a P/E ratio of 26.01.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.